Electrocompetent cells are bacterial strains that are capable of receiving and transferring foreign DNA by the process of electrotransformation. They are typically prepared by a time-consuming and labor-intensive method that involves extensive washing and centrifugation, as well as maintaining the cells at an ice-cold temperature. The traditional procedure also results in a low transformation efficiency, making it difficult to generate high quality clones using this technique.
Market Dynamics:
There is a rise in research activities and funding activities in molecular cloning studies. This in turn is expected to boost the demand for competent cells as they are highly efficacious in various biotechnology procedures. This factor is expected to support growth of the global electrocompetent cells market over the forecast period.
However, the need for skilled professionals having sound technical knowledge is one of the major factors expected to hamper growth of the global electrocompetent cells market over the forecast period.
Key features of the study:
- This report provides in-depth analysis of the global electrocompetent cells market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global electrocompetent cells market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., New England Biolabs, Inc., GenScript Biotech Corporation, Lucigen Corporation, Takara Bio Inc., Delphi Genetics S.A., IBA GmbH, Scarab Genomics LLC, Zymo Research Corporation, Bioline GmbH (Meridian Bioscience), and Cell Applications, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global electrocompetent cells market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global electrocompetent cells market
Detailed Segmentation:
- Global Electrocompetent Cells Market, By Application:
- Cloning
- Protein Expression
- Mutagenesis
- Genomic DNA Library Construction
- Antibody Production
- High-Throughput Screening
- Others
- Global Electrocompetent Cells Market, By Cell Type
- Escherichia coli (E. coli)
- Saccharomyces cerevisiae (S. cerevisiae)
- Bacillus subtilis (B. subtilis)
- Pseudomonas putida (P. putida)
- Streptococcus pneumoniae (S. pneumoniae)
- Others
- Global Electrocompetent Cells Market, By Transformation Efficiency:
- High Efficiency Cells
- Ultra-High Efficiency Cells
- Global Electrocompetent Cells Market, By Packaging Format:
- Tubes
- Plates
- Custom Formats
- Global Electrocompetent Cells Market, By End User:
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Contract Research Organizations (CROs)
- Others
- Global Electrocompetent Cells Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- Company Profiles:
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Agilent Technologies, Inc.
- QIAGEN N.V.
- Bio-Rad Laboratories, Inc.
- New England Biolabs, Inc.
- GenScript Biotech Corporation
- Lucigen Corporation
- Takara Bio Inc.
- Delphi Genetics S.A.
- IBA GmbH
- Scarab Genomics LLC
- Zymo Research Corporation
- Bioline GmbH (Meridian Bioscience)
- Cell Applications, Inc.